Akeso announced that the first patient has been dosed in its Phase II study (AK146D1-201) of AK146D1, a TROP2/Nectin-4 bispecific antibody-drug conjugate. This is an early clinical milestone that modestly de-risks the program ahead of later efficacy and safety readouts.
Akeso announced that the first patient has been dosed in its Phase II study (AK146D1-201) of AK146D1, a TROP2/Nectin-4 bispecific antibody-drug conjugate. This is an early clinical milestone that modestly de-risks the program ahead of later efficacy and safety readouts.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.25
